Literature DB >> 30697352

"Save the Last Dance" for Cardiovascular Magnetic Resonance.

Sophie I Mavrogeni1, George Markousis-Mavrogenis1, Genovefa Kolovou1.   

Abstract

Despite high mortality, cardiovascular disease (CVD) is underestimated in autoimmune rheumatic diseases (ARDs), due to its atypical presentation. The multi-faceted nature of CVD in ARDs created the need of a dedicated outpatient cardio-rheumatic clinic. Clinical examination, rest/exercise ECG, echocardiography, nuclear techniques and cardiac catheterisation were used as first-line diagnostic tools. Although the currently used non-invasive modalities perform well in cardiology, they are unable to diagnose the complex CVD pathophysiology of ARDs. The application of cardiovascular magnetic resonance (CMR) offers some significant advantages. CMR is versatile and can be used to perform functional, stress-rest perfusion, fibrosis and evaluation of great, peripheral and coronary vessels patency, without the use of ionising radiation, allowing early diagnosis of CVD and prompting modifications of anti-rheumatic and cardiac treatment.

Entities:  

Keywords:  Echocardiography; cardiovascular magnetic resonance; coronary artery disease; myocardial perfusion-fibrosis; myocarditis; nuclear imaging; rheumatic cardiovascular disease; spondyloarthropathy; vasculitis

Year:  2018        PMID: 30697352      PMCID: PMC6331770          DOI: 10.15420/ecr.2018.19.1

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN: 1758-3756


  32 in total

1.  Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets.

Authors:  Armen Yuri Gasparyan
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Myocarditis and subclavian stenosis in Takayasu arteritis.

Authors:  Sophie Mavrogeni; Menelaos N Manoussakis
Journal:  Int J Cardiol       Date:  2009-05-31       Impact factor: 4.164

3.  Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy.

Authors:  Sophie Mavrogeni; Kostas Spargias; Vyron Markussis; Genovefa Kolovou; Eftichia Demerouti; Evangelia Papadopoulou; George Stavridis; Loukas Kaklamanis; Marouso Douskou; Pantelis Constantoulakis; Dennis V Cokkinos
Journal:  Inflamm Allergy Drug Targets       Date:  2009-12

Review 4.  Mechanisms of disease: atherosclerosis in autoimmune diseases.

Authors:  Yaniv Sherer; Yehuda Shoenfeld
Journal:  Nat Clin Pract Rheumatol       Date:  2006-02

Review 5.  Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

Authors:  Deborah P M Symmons; Sherine E Gabriel
Journal:  Nat Rev Rheumatol       Date:  2011-05-31       Impact factor: 20.543

Review 6.  Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives.

Authors:  George D Kitas; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

7.  Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95.

Authors:  Lena Björnådal; Li Yin; Fredrik Granath; Lars Klareskog; Anders Ekbom
Journal:  J Rheumatol       Date:  2004-04       Impact factor: 4.666

8.  Determinants of morbidity and mortality of systemic sclerosis in Canada.

Authors:  Firas F Al-Dhaher; Janet E Pope; Janine M Ouimet
Journal:  Semin Arthritis Rheum       Date:  2008-08-15       Impact factor: 5.532

9.  Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC).

Authors:  Rosa Sicari; Petros Nihoyannopoulos; Arturo Evangelista; Jaroslav Kasprzak; Patrizio Lancellotti; Don Poldermans; Jen-Uwe Voigt; Jose Luis Zamorano
Journal:  Eur J Echocardiogr       Date:  2008-07

10.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

Authors:  J Antonio Aviña-Zubieta; Hyon K Choi; Mohsen Sadatsafavi; Mahyar Etminan; John M Esdaile; Diane Lacaille
Journal:  Arthritis Rheum       Date:  2008-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.